Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05672108
Other study ID # 22067
Secondary ID NCI-2022-1043622
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 12, 2023
Est. completion date October 31, 2024

Study information

Verified date June 2023
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor's blood supply. As a result, the tumor is exposed to a high dose of chemotherapy, and is also deprived of nutrients and oxygen. TACE can be effective at controlling or stopping the growth of lung tumors.


Description:

PRIMARY OBJECTIVE: I. To determine safety and efficacy (local progression free survival) of chemoembolization of lung cancer that is chemorefractory, unresectable, and unablatable. OUTLINE: Patients receive lung chemoembolization using Lipiodol, mitomycin, and Embospheres. Response to treatment is evaluated on computed tomography (CT) scans.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date October 31, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Non-small cell lung cancer (any stage), with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient cannot tolerate systemic therapy), and that are not amenable to resection, thermal ablation, or ablative radiation therapy - Lung-dominant disease (majority of active tumor volume is in the chest) - At least 18 years old Exclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status > 2 - Oxygen saturation < 92% on room air - Forced expiratory volume in 1 second (FEV1) < 60% - No measurable treatable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (for example, unable to measure tumor size on CT, or lung nodules are all < 1 cm) - Life expectancy < 6 months - Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, magnetic resonance imaging [MRI], or direct pressure measurement) - Recent pulmonary embolism (within 3 months) - Pulmonary arteriovenous malformation - Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month) - Symptomatic heart failure (American College of Cardiology [ACC]/American Heart Association [AHA] stage C or D) - Left bundle branch block (contraindication to pulmonary angiography) - Renal failure (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m^2) - Pregnancy or intent to become pregnant - Breast feeding - Altered mental status that would interfere with consent or follow-up - Platelets < 50,000 (after transfusion, if needed) - International normalized ratio (INR) > 2 (after transfusion, if needed) - Hemoglobin < 7 (after transfusion, if needed) - Hyperthyroidism or history of hyperthyroidism, including subclinical hyperthyroidism (contraindication to lipiodol) - Planned radioactive iodine imaging or therapy (contraindication to lipiodol) - Allergy to lipiodol or mitomycin - Allergy to iodinated contrast that cannot be treated with steroid / diphenhydramine premedication - Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, or that would affect subject safety

Study Design


Intervention

Procedure:
Computed Tomography
Undergo CT
Drug:
Ethiodized Oil
Given IA
Mitomycin
Given IA
Procedure:
Transarterial Chemoembolization
Undergo TACE
Device:
Tris-acryl Gelatin Microspheres
Given IA

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local progression free survival Progression is determined using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. criteria, compared to the scan immediately prior to treatment of that territory, using the 2 largest measurable lesions per treated territory. Local progression-free survival will be estimated using the Kaplan-Meier method. Time from the initial transarterial chemoembolization (TACE) treatment to progression in a completely treated territory (or touching the border of a completely treated area), or death from any cause, assessed at 6 months
Primary Incidence of adverse events Complications will be classified using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The rate of complications can be estimated with a standard error of less than 10%. Further, any complication that occurs with a 10% incidence will be observed with greater than 95% probability. Up to 3 months after the last chemoembolization procedure
Secondary Objective response rate (best response) Evaluated on a per-treatment basis, using RECIST version 1.1 criteria. Within 3 months of treatment
Secondary Overall survival Will be estimated using the Kaplan-Meier method. Up to 9 months
Secondary Progression-free survival Will be estimated using the Kaplan-Meier method. Up to 9 months
Secondary Bronchial versus pulmonary artery blood supply Percentage of treatments where target tumors were supplied by bronchial artery, non-bronchial systemic artery, or pulmonary artery, based on catheter angiography. Confidence intervals of proportions will be estimated using the equal-tailed Jeffreys prior interval. Up to 9 months
Secondary Lipiodol retention in treated tumors Correlation between lipiodol retention and change in tumor size will be evaluated using Spearman's rank correlation coefficient (rho) and Spearman's test. 4-6 weeks post-procedure
Secondary Growth of TACE targeted lesions versus non-TACE targeted lesions Percentage change in size (largest diameter) of the largest treated, compared to the largest untreated tumor will be evaluated using the Wilcoxon signed-rank test. 4-6 weeks post-procedure
See also
  Status Clinical Trial Phase
Withdrawn NCT04989283 - Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer Phase 2
Recruiting NCT05106374 - Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Terminated NCT03707925 - Bronchoscopic Laser Ablation of Peripheral Lung Tumors N/A
Active, not recruiting NCT04013542 - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Phase 1
Not yet recruiting NCT06427369 - An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer Phase 1
Recruiting NCT04929041 - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Phase 2/Phase 3
Recruiting NCT04073745 - Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer Phase 1
Recruiting NCT05830058 - Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Phase 2
Active, not recruiting NCT03637816 - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Phase 2/Phase 3
Recruiting NCT04298606 - A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence Early Phase 1
Recruiting NCT06122064 - A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer N/A
Recruiting NCT05802186 - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study N/A
Recruiting NCT03634241 - Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study Phase 2
Recruiting NCT04314401 - National Cancer Institute "Cancer Moonshot Biobank"
Recruiting NCT05493566 - Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Early Phase 1
Suspended NCT05501665 - Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer Phase 1/Phase 2
Withdrawn NCT04061590 - Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Phase 2
Recruiting NCT06225427 - Gilteritinib for the Treatment of ALK NSCLC Phase 1
Withdrawn NCT04085081 - Physical Activity Intervention Before and After Surgery in Older Adults With Lung Cancer and Their Family Caregivers N/A
Active, not recruiting NCT03939481 - Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer